tradingkey.logo

enVVeno Medical Corp

NVNO
查看詳細走勢圖
10.420USD
+1.070+11.44%
收盤 02/06, 16:00美東報價延遲15分鐘
6.02M總市值
虧損本益比TTM

enVVeno Medical Corp

10.420
+1.070+11.44%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+11.44%

5天

-12.66%

1月

-18.08%

6月

+119.83%

今年開始到現在

-7.20%

1年

+238.31%

查看詳細走勢圖

TradingKey enVVeno Medical Corp股票評分

單位: USD 更新時間: 2026-02-06

操作建議

enVVeno Medical Corp當前公司基本面數據相對謹慎,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名184/392位。機構持股佔比非常高,近一月多位分析師給出公司評級為持有。最高目標價為12.50。中期看,股價處於下降通道。近一個月,市場表現非常差,但技術面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

enVVeno Medical Corp評分

相關信息

行業排名
184 / 392
全市場排名
352 / 4521
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

enVVeno Medical Corp亮點

亮點風險
enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
估值高估
公司最新PE估值-0.28,處於3年歷史高位
機構減倉
最新機構持股169.95K股,環比減少28.78%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉834.00股
活躍度增加
近期活躍度增加,過去20天平均換手率8.32

分析師目標

基於 1 分析師
持有
評級
12.500
目標均價
+1517.29%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

enVVeno Medical Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

enVVeno Medical Corp簡介

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
公司代碼NVNO
公司enVVeno Medical Corp
CEOBerman (Robert A)
網址https://envveno.com/
KeyAI